The company’s iPSC-derived CAR-expressing NK cells and T cells are expected to enter clinical trials for a range of hematological and solid cancers in 2022.
PHILADELPHIA, Feb. 17, 2021 — Century Therapeutics, a leading cell therapy company developing induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, today announced a significant expansion of its operational and laboratory space in Philadelphia, as well as progress on its manufacturing facility in Branchburg, NJ, paving the way for a strong technical foundation as the company scales up its in-house research and development capabilities. [Read more…]